Literature DB >> 31843812

Isobolographic Analysis of Antiseizure Activity of the GABA Type A Receptor-Modulating Synthetic Neurosteroids Brexanolone and Ganaxolone with Tiagabine and Midazolam.

Shu-Hui Chuang1, Doodipala Samba Reddy2.   

Abstract

Epilepsy is often treated with a combination of antiepileptic drugs. Although neurosteroids are potent anticonvulsants, little is known about their combination potential for the treatment of refractory epilepsy. Here, we investigated the combination efficacy of neurosteroids allopregnanolone (AP, brexanolone) and ganaxolone (GX) with the GABA-reuptake inhibitor tiagabine (TG) or the benzodiazepine midazolam (MDZ) on tonic inhibition in dentate gyrus granule cells and seizure protection in the hippocampus kindling and 6-Hz seizure models. Isobolographic analysis indicated that combinations of GX and TG or AP and TG at three standard ratios (1:1, 3:1, and 1:3) displayed significant synergism in augmenting tonic inhibition. In pharmacological studies, GX, AP, and TG produced dose-dependent antiseizure effects in mice (ED50 = 1.46, 4.20, and 0.20 mg/kg, respectively). The combination of GX and TG at the fixed ratio of 1:1 exerted the greatest combination index (CI = 0.53), indicating strong synergistic interaction in seizure protection. In addition, combination regimens of AP and TG showed robust synergism for seizure protection (CI = 0.4). Finally, combination regimens of GX and MDZ elicited synergistic (CI = 0.6) responses for seizure protection. These results demonstrate striking synergism of neurosteroids and TG combination for seizure protection, likely because of their effects at extrasynaptic GABA type A (GABA-A) receptors from TG-induced elevation in GABA levels. Superadditive antiseizure activity of neurosteroid-MDZ combinations may stem from their actions at both synaptic and extrasynaptic GABA-A receptors. Together, these findings provide a potential mechanistic basis for combination potential of neurosteroids with TG or benzodiazepines for the management of refractory epilepsy, status epilepticus, and seizure disorders. SIGNIFICANCE STATEMENT: This paper investigates for the first time the potential synergistic interactions between two neurosteroids with anticonvulsant properties, allopregnanolone (brexanolone) and the very similar synthetic analog, ganaxolone, and two conventional antiepileptic drugs active at GABA type A receptors: the GABA-reuptake inhibitor tiagabine and a benzodiazepine, midazolam. The results demonstrate a synergistic protective effect of neurosteroid-tiagabine combinations, as well as neurosteroid-midazolam regimens in seizure models.
Copyright © 2020 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31843812      PMCID: PMC7011113          DOI: 10.1124/jpet.119.261735

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  70 in total

1.  Which GABA(A) receptor subunits are necessary for tonic inhibition in the hippocampus?

Authors:  Joseph Glykys; Edward O Mann; Istvan Mody
Journal:  J Neurosci       Date:  2008-02-06       Impact factor: 6.167

2.  Extrasynaptic γ-aminobutyric acid type A receptor-mediated sex differences in the antiseizure activity of neurosteroids in status epilepticus and complex partial seizures.

Authors:  Doodipala Samba Reddy; Chase Matthew Carver; Bryan Clossen; Xin Wu
Journal:  Epilepsia       Date:  2019-03-20       Impact factor: 5.864

Review 3.  Basic mechanisms of gabitril (tiagabine) and future potential developments.

Authors:  B S Meldrum; A G Chapman
Journal:  Epilepsia       Date:  1999       Impact factor: 5.864

Review 4.  Combination therapy in epilepsy: when and what to use.

Authors:  Patrick Kwan; Martin J Brodie
Journal:  Drugs       Date:  2006       Impact factor: 9.546

5.  Modification of seizure activity by electrical stimulation. II. Motor seizure.

Authors:  R J Racine
Journal:  Electroencephalogr Clin Neurophysiol       Date:  1972-03

6.  Zinc reduces antiseizure activity of neurosteroids by selective blockade of extrasynaptic GABA-A receptor-mediated tonic inhibition in the hippocampus.

Authors:  Shu-Hui Chuang; Doodipala Samba Reddy
Journal:  Neuropharmacology       Date:  2018-11-22       Impact factor: 5.250

7.  Felbamate, gabapentin and topiramate as adjuvant antiepileptic drugs in experimental models of epilepsy.

Authors:  S J Czuczwar; K Przesmycki
Journal:  Pol J Pharmacol       Date:  2001 Jan-Feb

8.  Characterization of the anticonvulsant properties of ganaxolone (CCD 1042; 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one), a selective, high-affinity, steroid modulator of the gamma-aminobutyric acid(A) receptor.

Authors:  R B Carter; P L Wood; S Wieland; J E Hawkinson; D Belelli; J J Lambert; H S White; H H Wolf; S Mirsadeghi; S H Tahir; M B Bolger; N C Lan; K W Gee
Journal:  J Pharmacol Exp Ther       Date:  1997-03       Impact factor: 4.030

9.  Chemogenetic Isolation Reveals Synaptic Contribution of δ GABAA Receptors in Mouse Dentate Granule Neurons.

Authors:  Min-Yu Sun; Hong-Jin Shu; Ann Benz; John Bracamontes; Gustav Akk; Charles F Zorumski; Joe Henry Steinbach; Steven J Mennerick
Journal:  J Neurosci       Date:  2018-08-03       Impact factor: 6.167

Review 10.  Neurosteroid binding sites on GABA(A) receptors.

Authors:  Alastair M Hosie; Megan E Wilkins; Trevor G Smart
Journal:  Pharmacol Ther       Date:  2007-04-21       Impact factor: 12.310

View more
  12 in total

Review 1.  Post-Traumatic Epilepsy and Comorbidities: Advanced Models, Molecular Mechanisms, Biomarkers, and Novel Therapeutic Interventions.

Authors:  Victoria M Golub; Doodipala Samba Reddy
Journal:  Pharmacol Rev       Date:  2022-04       Impact factor: 25.468

2.  Structure-Activity Relationship of Neuroactive Steroids, Midazolam, and Perampanel Toward Mitigating Tetramine-Triggered Activity in Murine Hippocampal Neuronal Networks.

Authors:  Shane Antrobus; Brandon Pressly; Atefeh Mousavi Nik; Heike Wulff; Isaac N Pessah
Journal:  Toxicol Sci       Date:  2021-04-12       Impact factor: 4.849

Review 3.  Neurosteroid replacement therapy for catamenial epilepsy, postpartum depression and neuroendocrine disorders in women.

Authors:  Doodipala Samba Reddy
Journal:  J Neuroendocrinol       Date:  2021-09-10       Impact factor: 3.870

4.  Phenobarbital as alternate anticonvulsant for organophosphate-induced benzodiazepine-refractory status epilepticus and neuronal injury.

Authors:  Doodipala Samba Reddy; Dheepthi Perumal; Victoria Golub; Andy Habib; Ramkumar Kuruba; Xin Wu
Journal:  Epilepsia Open       Date:  2020-04-14

Review 5.  Nutritional Impact on Metabolic Homeostasis and Brain Health.

Authors:  Lionel Carneiro; Luc Pellerin
Journal:  Front Neurosci       Date:  2022-01-27       Impact factor: 4.677

Review 6.  Super-Refractory Status Epilepticus: Prognosis and Recent Advances in Management.

Authors:  Batool F Kirmani; Katherine Au; Lena Ayari; Marita John; Padmashri Shetty; Robert J Delorenzo
Journal:  Aging Dis       Date:  2021-07-01       Impact factor: 6.745

7.  Allopregnanolone and perampanel as adjuncts to midazolam for treating diisopropylfluorophosphate-induced status epilepticus in rats.

Authors:  Ashish Dhir; Donald A Bruun; Michelle Guignet; Yi-Hua Tsai; Eduardo González; Jonas Calsbeek; Joan Vu; Naomi Saito; Daniel J Tancredi; Danielle J Harvey; Pamela J Lein; Michael A Rogawski
Journal:  Ann N Y Acad Sci       Date:  2020-09-11       Impact factor: 5.691

8.  Neurosteroids and Seizure Activity.

Authors:  Barbara Miziak; Magdalena Chrościńska-Krawczyk; Stanisław J Czuczwar
Journal:  Front Endocrinol (Lausanne)       Date:  2020-09-30       Impact factor: 5.555

Review 9.  Mens Sana in Corpore Sano: Does the Glycemic Index Have a Role to Play?

Authors:  Lionel Carneiro; Corinne Leloup
Journal:  Nutrients       Date:  2020-09-29       Impact factor: 5.717

Review 10.  How Antidepressant Drugs Affect the Antielectroshock Action of Antiseizure Drugs in Mice: A Critical Review.

Authors:  Kinga K Borowicz-Reutt
Journal:  Int J Mol Sci       Date:  2021-03-03       Impact factor: 6.208

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.